Share

    


Home / Search Results

Search Results

You searched for:

ACCCBuzz spoke with Luis E. Raez, MD, FACP, FCCP, to learn more about the importance of closing the gap in access to biomarker testing and strategies to improve equity and inclusion in precision medicine.
With the variety of models and titles that have emerged under precision medicine stewardship, learn how one cancer program is breaking down the this complex landscape into streamlined workflows to improve efficiency and better support growing test volumes.
ACCC shares how a precision medicine steward—a dedicated navigator focused specifically on biopsy samples and biomarker testing processes and results—can make a daunting biomarker testing process incredibly efficient for cancer programs and practices everywhere.
Dr. John Strickler from Duke Cancer Institute sat down with ACCCBuzz to talk about molecular profiling and data, including the cancer institute's own journey in oncology precision medicine.
Introduced in 2021, the Cancer Patient Equity Act seeks to provide coverage of certain cancer diagnostic and laboratory tests under Medicare, Medicaid, and the Children's Health Insurance Program, and more.
ACCCBuzz shares highlights from the NCCN Policy Summit: Reducing the Cancer Burden through Prevention and Early Detection, highlighting the real impacts felt by patients and providers in cancer risk identification and reduction.
Care optimization is everything in today’s rapidly changing healthcare landscape. Learn how ACCC's nationwide quality improvement (QI) initiative helped Southern Ohio Medical Center Cancer Center develop and implement plans to support the optimization of care for patients diagnosed with Stages III and IV non-small cell lung cancer (NSCLC).
On September 16, the National Comprehensive Cancer Network convened experts and stakeholders in D.C. for a policy summit spotlighting today’s cancer screening and prevention landscape. Learn what speakers discussed, including what changes need to happen to create an equitable future for all people at risk—or not—for cancer.
To fill a care gap, The James Cancer Hospital opened a new set of front doors to its facility—The James Cancer Diagnostic Center—to ensure all patients with a concern for cancer could be quickly evaluated, even if they didn’t have a confirmed diagnosis.
Measurable residual disease (MRD) has gained traction as a compelling marker for disease status across various hematologic malignancies, including multiple myeloma. Learn how MRD is uniquely suited to help evaluate the depth of treatment response.
With data already demonstrating the role of MRD for CLL response assessment and prognosis, cancer programs should prepare themselves for implementation of MRD testing for appropriate patients.
Advocating on behalf of their patients and programs, ACCC members from 14 states participated in Virtual Hill Day, speaking with Congress and their staff on key legislation asks regarding access to care, telehealth, prior authorizations, and more.
Carolina Blood and Cancer Care Associate's No One Left Alone (or NOLA) initiative is a multi-phase pilot program aimed at lessening disparities in cancer care in three key areas: care access, biomarker testing, and clinical trials.
As precision medicine becomes more common in the management of lung cancer, little is understood about the patient experience with biomarker testing, particularly of underserved patients. This study used survey and focus group methodology to determine patient perspectives on the educational needs within this community.
ACCC has launched Transforming Complex to Clear—a precision medicine campaign that has developed a range of tools and resources to help bring clarity to complex patient care decisions. Designed for multidisciplinary cancer teams, learn more about how these resources can enable clinicians to make educated and confident decisions.
In launching its new campaign, "Transforming Complex To Clear," ACCC brought together expert panelists to discuss effective practices and offer tips to address current barriers to biomarker testing in the community setting.
This ACCC education program shares key highlights from a national survey of thoracic surgeons, radiation oncologists, and medical oncologists on the barriers that exist in the ideal management of patients with NSCLC.